Evolus to Report First Quarter Financial Results on May 7, 2024
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Announces Results from European Head-to-Head Filler Trial
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)